GHRP-2 vs GHRP-6
Written by the Pure Peptides editorial team
Reviewed by Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer · Reviewed
Published · Updated · 18 references
GHRP-2 and GHRP-6 are different molecules: each is a synthetic six-residue peptide, and they differ in composition, including how many of their residues are D-configured.
Structure at a glance
GHRP-2
GHRP-6
NH2: C-terminal amide. A raised D marks a D-amino acid. 2Nal: 2-naphthylalanine. Codes are three-letter amino acid codes.
Drawn from the product database. Each measure's bars share one scale.
| Property | GHRP-2 | GHRP-6 |
|---|---|---|
| What it is | A synthetic six-residue peptide with a free N-terminal amine and a C-terminal amide. | A synthetic six-residue peptide with a free N-terminal amine and a C-terminal amide. |
| How they relate | Different molecules. GHRP-2 is a synthetic hexapeptide in which three of the six residues are D-configured. GHRP-6 is a synthetic hexapeptide in which two of the six residues are D-configured. | |
| CAS number | 158861-67-7 | 87616-84-0 |
| Molecular formula | C45H55N9O6 | C46H56N12O6 |
| Molecular weight | 817.99 g/mol | 873.01 g/mol |
| Sequence | D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Evidence base | Human data on GHRP-2 are narrow, and no registered study tests it as a treatment.[1] | More than 80 published human studies, mostly single-dose; repeated use lasted a week at most.[14] Published controlled trials with a clinical outcome gave it with epidermal growth factor; the larger missed its primary endpoint.[15] |
| Regulatory status | The FDA has not approved GHRP-2. Pralmorelin hydrochloride is approved in Japan as a diagnostic agent.[17] | The FDA has not approved GHRP-6 for human use. |
| Compared head-to-head? | Yes: a 1998 study tested GHRP-2 and GHRP-6 in conscious swine.[3] Another 1998 study tested both in human pituitary and hypothalamic membranes.[4] Further comparisons found in PubMed (searched October 2026).[5] | |
| Handling difference | Neither contains cysteine or methionine. GHRP-2 carries one tryptophan and GHRP-6 two, and tryptophan can oxidize. | |
How GHRP-2 and GHRP-6 differ
GHRP-2 and GHRP-6 are different molecules. Both are synthetic six-residue peptides with a free N-terminal amine and a C-terminal amide. Their compositions differ. Three of GHRP-2's six residues are D-configured, it carries one tryptophan, and one of its residues, 2-naphthylalanine, does not occur in proteins. Two of GHRP-6's six residues are D-configured, and it carries two tryptophans.
A small human study often cited for GHRP-6 tested GHRP-2 and a third peptide.[6] GHRP-6 appears in it only in the introduction and was not tested.[6] No finding from that study was obtained with GHRP-6. FDA's review cites reports of increased insulin requirement, infection, pancreatitis and deaths among critically ill study subjects given GHRP-2.[7] Reports like these cannot show that GHRP-2 caused the events or how often they occur.
More than 80 published studies have given GHRP-6 to people, most of them single-dose tests; published studies of repeated use lasted a week at most.[14] The published controlled trials with a clinical outcome gave it together with epidermal growth factor, and the larger one missed its primary endpoint.[15] ClinicalTrials.gov lists no trial of GHRP-6.[2] The Cuban public registry lists at least seven, and no results have been located for four of them.[16] An author of the 1990 human study of GHRP-6 held an inventor interest.[8] The literature reviewed for GHRP-6 reports no serious safety finding from its human studies.
Neither peptide contains cysteine, methionine, asparagine, glutamine or aspartate. Each carries a tryptophan indole, which air, light and trace metals can oxidize. Heated in solution, GHRP-6 degraded by C-terminal deamidation, hydrolysis and head-to-tail cyclization, and oxidized tryptophan forms were minor.[18] In GHRP-6, the histidine coordinates transition metals, and trace metal contamination promotes tryptophan oxidation. Each is cationic and carries aromatic rings, so each can adsorb to surfaces both electrostatically and hydrophobically. In GHRP-2, those rings include the fused bicyclic naphthalene of its 2-naphthylalanine. In each, mass spectrometry cannot verify the configuration of the D-residues, since a D-residue and its L-form are identical in mass.
The FDA has not approved either GHRP-2 or GHRP-6. Pralmorelin hydrochloride, a salt of GHRP-2, is approved in Japan as a diagnostic agent.[17] Pralmorelin hydrochloride is the active ingredient of a diagnostic medicine sold there under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.
Have GHRP-2 and GHRP-6 been compared directly?
A 1998 study tested GHRP-2 and GHRP-6 in conscious swine.[3] Results are reported for each compound in that model. Five studies in cells or tissue tested GHRP-2 and GHRP-6 in the same system. Two used human material: pituitary and hypothalamic membranes (1998)[4] and cell cultures from pituitary tumors (1996).[9] Three used animal pituitary cells: rat (1997),[10] sheep and rat (1996)[11] and sheep (1997).[12] Results are reported for each compound in each assay. A 2013 study tested both in mice.[13] Results are reported for each compound in that model.
Read more on each compound
GHRP-2
Frequently Asked Questions
Is GHRP-2 the same as GHRP-6?+−
GHRP-2 and GHRP-6 are different molecules, though each is a synthetic six-residue peptide. Three of GHRP-2's residues are D-configured, and one, 2-naphthylalanine, does not occur in proteins. Two of GHRP-6's residues are D-configured, and it carries two tryptophans.
Does research on GHRP-2 apply to GHRP-6?+−
A small human study often cited for GHRP-6 tested GHRP-2 and a third peptide, and GHRP-6 was not tested in it. No finding from that study was obtained with GHRP-6.
References
- 1Registry searches, 16 October 2026: ClinicalTrials.gov, the EU Clinical Trials Register, ANZCTR, and Japan's jRCT and UMIN-CTR. No registered study tests GHRP-2 as a treatment; registered studies use it as a diagnostic test or in anti-doping research.
- 2ClinicalTrials.gov v2 API, per-compound queries by intervention and general term, 27 August 2026. GHRP-6 returns zero registered studies, as it still did on 16 October 2026.
- 4Muccioli G, Ghè C, Ghigo MC, Papotti M, Arvat E, Boghen MF, Nilsson MH, Deghenghi R, Ong H, Ghigo E. J Endocrinol. 1998;157(1):99-106. PMID 9614363.
- 5
PubMed search, 3 October 2026 (records to 2 October 2026)
40 records, including the 7 direct comparisons described above.
Exact query (NCBI E-utilities): ("GHRP-2"[tiab] OR "GHRP 2"[tiab] OR "GHRP2"[tiab] OR "pralmorelin"[tiab] OR "growth hormone-releasing peptide-2"[tiab] OR "growth hormone releasing peptide-2"[tiab] OR "growth hormone releasing peptide 2"[tiab]) AND ("GHRP-6"[tiab] OR "GHRP 6"[tiab] OR "GHRP6"[tiab] OR "growth hormone-releasing peptide-6"[tiab] OR "growth hormone releasing peptide-6"[tiab] OR "growth hormone releasing peptide 6"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])
View this search on PubMed - 6Arvat E, et al. Peptides 1997. PMID 9285939. DOI: 10.1016/s0196-9781(97)00016-8. GHRP-2 and hexarelin only; GHRP-6 was not administered.
- 7US Food and Drug Administration. Web page, retrieved 4 October 2026. fda.gov
- 13Zeng P, Chen JX, Yang B, Zhi X, Guo FX, Sun ML, Wang JL, Wei J. Peptides. 2013;50:42-49. PMID 24113541.
- 14PubMed searches via NCBI E-utilities, run 16 October 2026, for GHRP-6 under its name variants and its sequence. Limited to clinical trial and clinical study publication types: 56 records, 38 of them giving GHRP-6 to people. Limited to humans: 322 records, 97 giving it to people. Some describe the same participants.
- 15Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, et al. J Clin Neurosci. 2026;152:112195. doi:10.1016/j.jocn.2026.112195. PMID 42462342. Randomized, open-label phase III trial; primary endpoint not met.
- 16WHO International Clinical Trials Registry Platform search portal, searches run 16 October 2026: at least seven interventional trials of the same peptide in the Cuban Public Registry of Clinical Trials, registered from 2010 to 2026 under its name and under its sponsor's code. No results were located for four of them.
- 17Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Approval of pralmorelin hydrochloride for injection as a diagnostic agent on 22 October 2004, recorded in PMDA's 2014 re-examination report; current package insert revised July 2025. In Japanese. pmda.go.jp

Reviewed for scientific accuracy
Dr. Martina Rossi, PhD
PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer
Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.
Related comparisons
GHRP-6 vs Ipamorelin
GHRP-6 and Ipamorelin are different molecules: GHRP-6 is a synthetic six-residue peptide; Ipamorelin is a synthetic five-residue peptide.
Read ComparisonAOD-9604 vs HGH Fragment 176-191
AOD-9604 and HGH Fragment 176-191 are 16-residue peptides from the C-terminal end of human growth hormone that differ at one position.
Read ComparisonAOD-9604 vs Tesamorelin
AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.
Read Comparison

